ConductScience.org, home

Paper38406830

Genomic epidemiology and ceftazidime-avibactam high-level resistance mechanisms of Pseudomonas aeruginosa in China from 2010 to 2022.

Li X and 12 others. Emerg Microbes Infect, 2024. Cited by 14 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Genomic epidemiology and ceftazidime-avibactam high-level resistance mechanisms of Pseudomonas aeruginosa in China from 2010 to 2022. Papers, record 38406830. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38406830

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Genomic epidemiology and ceftazidime-avibactam high-level resistance mechanisms of Pseudomonas aeruginosa in China from 2010 to 2022.
PubMed
Journal
Emerg Microbes Infect
PubMed
Year
2024
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
14
iCite
Relative citation ratio, by iCite
3.4, provisional
iCite
Revised in PubMed
2024-03-16
PubMed

Authors13

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Li XXi
2Zhou LLongjie
3Lei TTailong
4Zhang XXiaofan
5Yao JJiayao
6He JJintao
7Liu HHaiyang
8Cai HHeng
9Ji JJingshu
10Zhu YYiwei
11Tu YYuexing
12Yu YYunsong
13Zhou HHuahttps://orcid.org/0000-0001-6397-3203

Source PubMed

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
CeftazidimeMajor topic
Pseudomonas InfectionsMajor topic
Azabicyclo CompoundsMajor topic
Humans
Pseudomonas aeruginosa
Anti-Bacterial Agents
Drug Resistance, Multiple, Bacterial
Drug Combinations
Genomics
Microbial Sensitivity Tests
beta-Lactamases

Source PubMed

References56

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
118,625,772
Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France.
Antimicrob Agents Chemother2008https://conductscience.org/library/papers/18625772PubMed
235,974,990High prevalence of blaVEB , blaGES and blaPER genes in beta-lactam resistant clinical isolates of Pseudomonas aeruginosa.AIMS Microbiol2022https://conductscience.org/library/papers/35974990PubMed
325,870,070Molecular characterization of ISCR1-mediated blaPER-1 in a non-O1, non-O139 Vibrio cholerae strain from China.Antimicrob Agents Chemother2015https://conductscience.org/library/papers/25870070PubMed
426,248,364Mutations in β-Lactamase AmpC Increase Resistance of Pseudomonas aeruginosa Isolates to Antipseudomonal Cephalosporins.Antimicrob Agents Chemother2015https://conductscience.org/library/papers/26248364PubMed
527,622,530Molecular Mechanism of Avibactam-Mediated β-Lactamase Inhibition.ACS Infect Dis2015https://conductscience.org/library/papers/27622530PubMed
629,514,274
Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party.
J Antimicrob Chemother2018https://conductscience.org/library/papers/29514274PubMed
733,083,833Molecular mechanisms driving the in vivo development of OXA-10-mediated resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of XDR Pseudomonas aeruginosa infections.J Antimicrob Chemother2021https://conductscience.org/library/papers/33083833PubMed
831,709,791Structural Insight into the Mechanism of Inhibitor Resistance in CTX-M-199, a CTX-M-64 Variant Carrying the S130T Substitution.ACS Infect Dis2020https://conductscience.org/library/papers/31709791PubMed
937,212,660Insertion of ISPa1635 in ISCR1 Creates a Hybrid Promoter for blaPER-1 Resulting in Resistance to Novel β-lactam/β-lactamase Inhibitor Combinations and Cefiderocol.Antimicrob Agents Chemother2023https://conductscience.org/library/papers/37212660PubMed
1032,246,147
In Vitro Activity of Imipenem/Relebactam and Ceftolozane/Tazobactam Against Clinical Isolates of Gram-negative Bacilli With Difficult-to-Treat Resistance and Multidrug-resistant Phenotypes-Study for Monitoring Antimicrobial Resistance Trends, United States 2015-2017.
Clin Infect Dis2021https://conductscience.org/library/papers/32246147PubMed
1137,140,037Proksee: in-depth characterization and visualization of bacterial genomes.Nucleic Acids Res2023https://conductscience.org/library/papers/37140037PubMed
1234,484,166Emergence of a KPC Variant Conferring Resistance to Ceftazidime-Avibactam in a Widespread ST11 Carbapenem-Resistant Klebsiella pneumoniae Clone in China.Front Microbiol2021https://conductscience.org/library/papers/34484166PubMed
1326,584,231OPLS3: A Force Field Providing Broad Coverage of Drug-like Small Molecules and Proteins.J Chem Theory Comput2016https://conductscience.org/library/papers/26584231PubMed
1427,402,011Structural and sequence analysis of class A β-lactamases with respect to avibactam inhibition: impact of Ω-loop variations.J Antimicrob Chemother2016https://conductscience.org/library/papers/27402011PubMed
1535,439,291
Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa).
Clin Infect Dis2022https://conductscience.org/library/papers/35439291PubMed
1636,399,436Hypermutator strains of Pseudomonas aeruginosa reveal novel pathways of resistance to combinations of cephalosporin antibiotics and beta-lactamase inhibitors.PLoS Biol2022https://conductscience.org/library/papers/36399436PubMed
1716,420,040Novel procedure for modeling ligand/receptor induced fit effects.J Med Chem2006https://conductscience.org/library/papers/16420040PubMed
1825,645,206Selection and molecular characterization of ceftazidime/avibactam-resistant mutants in Pseudomonas aeruginosa strains containing derepressed AmpC.J Antimicrob Chemother2015https://conductscience.org/library/papers/25645206PubMed
1921,905,107The VSGB 2.0 model: a next generation energy model for high resolution protein structure modeling.Proteins2011https://conductscience.org/library/papers/21905107PubMed
2033,045,347Pseudomonas aeruginosa epidemic high-risk clones and their association with horizontally-acquired β-lactamases: 2020 update.Int J Antimicrob Agents2020https://conductscience.org/library/papers/33045347PubMed

See all 56 references

Cited by11

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 14 citations.

PMIDTitleJournalYearIn PapersSource
42,479,024PER-14, a β-lactamase variant with reduced sensitivity to avibactam and relebactam.Antimicrob Agents Chemother2026https://conductscience.org/library/papers/42479024PubMed
42,429,474Emergence of ceftazidime-avibactam resistance mediated by KPC variants KPC-71 and KPC-78 in ST463 Pseudomonas aeruginosa.Microbiol Spectr2026https://conductscience.org/library/papers/42429474PubMed
41,892,432Novel Insights into Carbapenem Resistance: Mechanisms, Diagnostics, and Future Directions.Antibiotics (Basel)2026https://conductscience.org/library/papers/41892432PubMed
41,835,003The blaKPC-249 -mediated mechanism drives the transition of ST463 Pseudomonas aeruginosa from Ceftazidime-Avibactam sensitivity to resistance during clinical treatment.Front Cell Infect Microbiol2026https://conductscience.org/library/papers/41835003PubMed
41,630,025Genomic epidemiology and aztreonam-avibactam resistance mechanisms of Proteus mirabilis in china: an eight-year retrospective study.Ann Clin Microbiol Antimicrob2026https://conductscience.org/library/papers/41630025PubMed
41,195,361Study on resistance mechanisms and molecular epidemiology of carbapenem-resistant Pseudomonas aeruginosa to ceftazidime/avibactam in a certain region of China.Front Cell Infect Microbiol2025https://conductscience.org/library/papers/41195361PubMed
40,732,125Metagenome Analysis Reveals Changes in Gut Microbial Antibiotic Resistance Genes and Virulence Factors in Reintroduced Giant Pandas.Microorganisms2025https://conductscience.org/library/papers/40732125PubMed
40,600,143Identification of two KPC variants, KPC-204 and KPC-227, in ST11-K64 Klebsiella pneumoniae during prolonged hospitalization of a single patient.Front Microbiol2025https://conductscience.org/library/papers/40600143PubMed
40,142,580Antibiotic Resistance and Virulence Determinants of Pseudomonas aeruginosa Isolates Cultured from Hydrocarbon-Contaminated Environmental Samples.Microorganisms2025https://conductscience.org/library/papers/40142580PubMed
39,843,962Global phylogeography and genetic characterization of carbapenem and ceftazidime-avibactam resistant KPC-33-producing Pseudomonas aeruginosa.NPJ Antimicrob Resist2025https://conductscience.org/library/papers/39843962PubMed
39,592,545Multidrug resistance in Pseudomonas aeruginosa: genetic control mechanisms and therapeutic advances.Mol Biomed2024https://conductscience.org/library/papers/39592545PubMed

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/38406830

GET https://conductscience.org/api/papers/v1/38406830/references?page=2